Immunotherapy combo shows promise in Hard-to-Treat colorectal cancer
NCT ID NCT03388190
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether adding the immunotherapy drug nivolumab to standard chemotherapy could help people with a specific type of metastatic colorectal cancer (MSS/pMMR). Eighty participants received either the combination or chemotherapy alone. The main goal was to see if the combo slowed cancer growth. The study also tracked side effects to assess safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab and chemotherapy (oxaliplatin, 5-fluorouracil, leucovorin)
What this could lead to
If successful, this combination could offer a new treatment option that delays cancer progression for people with a common type of metastatic colorectal cancer.
What could go wrong
This is a phase 2 trial with only 80 participants, so results are preliminary. The added immunotherapy may not improve outcomes and could cause additional side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akershus University Hospital
Oslo, 1478, Norway
-
Haukeland University Hospital
Bergen, 5021, Norway
-
Hospital of Southern Norway, Department of Oncology
Kristiansand, 4604, Norway
-
Oslo University Hospital
Oslo, 0424, Norway
-
St Olav's Hospital - Trondheim University Hospital
Trondheim, 7006, Norway